Nick Devoogdt

List of Publications by Year
in descending order

131 papers	7,588 citations	41258 49 h-index	58464 82 g-index
135 all docs	135 docs citations	135 times ranked	7650 citing authors

#	Article	IF	Citations
1	The antigenâ€binding moiety in the driver's seat of CARs. Medicinal Research Reviews, 2022, 42, 306-342.	5.0	21
2	The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy. Molecular Cancer Therapeutics, 2022, 21, 159-169.	1.9	9
3	Abstract P3-02-05: Assessment of repeatability and uptake quantification of 68GaNOTA-anti-HER2 sdAb PET/CT in patients with locally advanced or metastatic breast cancer. Cancer Research, 2022, 82, P3-02-05-P3-02-05.	0.4	0
4	Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy. Pharmaceuticals, 2022, 15, 13.	1.7	22
5	Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177â€“Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model. Molecular Cancer Therapeutics, 2022, 21, 1136-1148.	1.9	5
6	Emerging applications of nanobodies in cancer therapy. International Review of Cell and Molecular Biology, 2022, , 143-199.	1.6	9
7	Phase I Trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. Journal of Nuclear Medicine, 2021, 62, 1097-1105.	2.8	67
8	Development and Characterization of Nanobodies Targeting the Kupffer Cell. Frontiers in Immunology, 2021, 12, 641819.	2.2	6
9	The Design and Preclinical Evaluation of a Single-Label Bimodal Nanobody Tracer for Image-Guided Surgery. Biomolecules, 2021, 11, 360.	1.8	8
10	Mechanisms Underlying Connexin Hemichannel Activation in Disease. International Journal of Molecular Sciences, 2021, 22, 3503.	1.8	27
11	Immunogenicity Risk Profile of Nanobodies. Frontiers in Immunology, 2021, 12, 632687.	2.2	97
12	Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade. Journal of Nuclear Medicine, 2021, 62, 1638-1644.	2.8	26
13	Direct Immobilization of Engineered Nanobodies on Gold Sensors. ACS Applied Materials & Interfaces, 2021, 13, 17353-17360.	4.0	20
14	Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimideâ€“Cysteine Chemistry. Pharmaceuticals, 2021, 14, 550.	1.7	15
15	Lyophilization of NOTA-sdAbs: First step towards a cold diagnostic kit for 68Ga-labeling. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 166, 194-204.	2.0	4
16	Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade. Molecular Therapy - Methods and Clinical Development, 2021, 22, 172-182.	1.8	11
17	Newer Bioconjugation Methods. , 2021, , 517-529.		1
18	Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor. Biomolecules, 2021, 11, 63.	1.8	13

#	Article	IF	Citations
19	The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Timeâ€™s a Charm. International Journal of Molecular Sciences, 2021, 22, 75.	1.8	87
20	An affinity-enhanced, broadly neutralizing heavy chainâ€“only antibody protects against SARS-CoV-2 infection in animal models. Science Translational Medicine, 2021, 13, eabi7826.	5.8	41
21	Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. EJNMMI Research, 2021, 11, 115.	1.1	5
22	A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 183.	6.9	12
23	Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha. Frontiers in Immunology, 2021, 12, 777524.	2.2	18
24	CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma. OncoImmunology, 2021, 10, 2000699.	2.1	9
25	Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33. International Journal of Molecular Sciences, 2020, 21, 310.	1.8	18
26	A nanobody-based nuclear imaging tracer targeting dipeptidyl peptidase 6 to determine the mass of human beta cell grafts in mice. Diabetologia, 2020, 63, 825-836.	2.9	20
27	Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours. Journal of Controlled Release, 2020, 317, 34-42.	4.8	115
28	Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. Biomolecules, 2020, 10, 1388.	1.8	42
29	Non-canonical roles of connexins. Progress in Biophysics and Molecular Biology, 2020, 153, 35-41.	1.4	14
30	Reshaping nanobodies for affinity purification on protein a. New Biotechnology, 2020, 57, 20-28.	2.4	5
31	Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging. Molecules, 2020, 25, 1838.	1.7	7
32	Preclinical Targeted Î±- and Î²â^'-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers, 2020, 12, 1017.	1.7	43
33	Design and preclinical evaluation of a single-label bimodal nanobody tracer for image-guided surgery (Conference Presentation). , 2020, , .		0
34	Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. Vaccines, 2019, 7, 85.	2.1	17
35	Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases. Pharmaceutics, 2019, 11, 376.	2.0	16
36	In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer. Cancers, 2019, 11, 1039.	1.7	3

#	Article	IF	Citations
37	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Cancers, 2019, 11, 872.	1.7	50
38	Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors. Journal of Controlled Release, 2019, 314, 1-11.	4.8	22
39	Ultrasound Molecular Imaging of Atherosclerosis With Nanobodies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2520-2530.	1.1	42
40	Increased Expression of Adherens Junction Components in Mouse Liver following Bile Duct Ligation. Biomolecules, 2019, 9, 636.	1.8	4
41	Theranostics in immuno-oncology using nanobody derivatives. Theranostics, 2019, 9, 7772-7791.	4.6	83
42	Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules, 2019, 9, 548.	1.8	43
43	Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery. Antibodies, 2019, 8, 12.	1.2	76
44	CAM-H2 effectively targets and treats HER2 positive brain lesions: A comparative preclinical study with trastuzumab. Annals of Oncology, 2019, 30, iii59.	0.6	3
45	Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages. Molecular Imaging and Biology, 2019, 21, 898-906.	1.3	69
46	Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[¹⁸F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios. Molecular Pharmaceutics, 2019, 16, 214-226.	2.3	21
47	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC: Cardiovascular Imaging, 2019, 12, 2015-2026.	2.3	66
48	Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis â€“ impact of radiochemistry on pharmacokinetics. Biological Chemistry, 2019, 400, 323-332.	1.2	19
49	Site-Selective Functionalization of Nanobodies Using Intein-Mediated Protein Ligation for Innovative Bioconjugation. Methods in Molecular Biology, 2019, 2033, 117-130.	0.4	4
50	Development of LAG-3 nanobodies as potent cancer imaging tracers. Annals of Oncology, 2019, 30, xi10-xi11.	0.6	0
51	Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. Bioorganic and Medicinal Chemistry, 2018, 26, 1939-1949.	1.4	32
52	Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20. New Biotechnology, 2018, 45, 69-79.	2.4	21
53	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. Journal of Nuclear Medicine, 2018, 59, 885-891.	2.8	101
54	Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model. Molecular Imaging and Biology, 2018, 20, 361-367.	1.3	42

#	Article	IF	Citations
55	Evaluation of [99mTc]Radiolabeled Macrophage Mannose Receptor-Specific Nanobodies for Targeting of Atherosclerotic Lesions in Mice. Molecular Imaging and Biology, 2018, 20, 260-267.	1.3	24
56	Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method. Nature Protocols, 2018, 13, 2330-2347.	5.5	27
57	An Efficient Method for Labeling Single Domain Antibody Fragments with ¹⁸F Using Tetrazine-<i>Trans</i>-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker. Bioconjugate Chemistry, 2018, 29, 4090-4103.	1.8	32
58	Site-Specific Radioactive Labeling of Nanobodies. Methods in Molecular Biology, 2018, 1827, 505-540.	0.4	11
59	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics, 2018, 8, 3559-3570.	4.6	85
60	Phase I results of CAM-H2: Safety profile and tumor targeting in patients.. Journal of Clinical Oncology, 2018, 36, e13017-e13017.	0.8	6
61	Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis. Molecular Imaging and Biology, 2017, 19, 49-58.	1.3	24
62	Limiting the protein corona: A successful strategy for inÂvivo active targeting of anti-HER2 nanobody-functionalized nanostars. Biomaterials, 2017, 123, 15-23.	5.7	36
63	Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery. Molecular Pharmaceutics, 2017, 14, 1145-1153.	2.3	76
64	Cytoplasmic versus periplasmic expression of site-specifically and bioorthogonally functionalized nanobodies using expressed protein ligation. Protein Expression and Purification, 2017, 133, 25-34.	0.6	16
65	Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation. Molecular Imaging and Biology, 2017, 19, 867-877.	1.3	54
66	Rational Design of Nanobody80 Loop Peptidomimetics: Towards Biased Î² 2 Adrenergic Receptor Ligands. Chemistry - A European Journal, 2017, 23, 9632-9640.	1.7	13
67	AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. Human Molecular Genetics, 2017, 26, 1353-1364.	1.4	26
68	Evaluation of Antiatherogenic Properties of Ezetimibe Using ³H-Labeled Low-Density-Lipoprotein Cholesterol and ^{99m}Tc-cAbVCAM1â€“5 SPECT in ApoE^{âˆ’/âˆ’} Mice Fed the Paigen Diet. Journal of Nuclear Medicine, 2017, 58, 1088-1093.	2.8	19
69	Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics, 2017, 16, 2828-2839.	1.9	57
70	131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. Clinical Cancer Research, 2017, 23, 6616-6628.	3.2	124
71	A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells. Scientific Reports, 2017, 7, 15130.	1.6	41
72	Al¹⁸F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging. Theranostics, 2017, 7, 2924-2939.	4.6	54

#	Article	IF	Citations
73	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget, 2017, 8, 41932-41946.	0.8	95
74	Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies. Current Pharmaceutical Design, 2017, 22, 6500-6518.	0.9	37
75	Sortase Aâ€mediated siteâ€specific labeling of camelid singleâ€domain antibodyâ€fragments: a versatile strategy for multiple molecular imaging modalities. Contrast Media and Molecular Imaging, 2016, 11, 328-339.	0.4	100
76	Emerging site-specific bioconjugation strategies for radioimmunotracer development. Expert Opinion on Drug Delivery, 2016, 13, 1149-1163.	2.4	40
77	Non-Invasive Imaging of Amyloid Deposits in a Mouse Model of AGel Using 99mTc-Modified Nanobodies and SPECT/CT. Molecular Imaging and Biology, 2016, 18, 887-897.	1.3	12
78	Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opinion on Biological Therapy, 2016, 16, 1035-1047.	1.4	119
79	Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies. Scientific Reports, 2016, 6, 35966.	1.6	11
80	Targeting of vascular cell adhesion molecule-1 by¹⁸F-labelled nanobodies for PET/CT imaging of inflamed atherosclerotic plaques. European Heart Journal Cardiovascular Imaging, 2016, 17, 1001-1008.	0.5	83
81	Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8. Molecular Therapy, 2016, 24, 890-902.	3.7	23
82	Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nature Communications, 2016, 7, 10321.	5.8	604
83	18F-nanobody for PET imaging of HER2 overexpressing tumors. Nuclear Medicine and Biology, 2016, 43, 247-252.	0.3	86
84	Phase I Study of ⁶⁸Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. Journal of Nuclear Medicine, 2016, 57, 27-33.	2.8	317
85	Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1. Journal of Biological Chemistry, 2015, 290, 4022-4037.	1.6	63
86	PET Imaging of Macrophage Mannose Receptorâ€“Expressing Macrophages in Tumor Stroma Using ¹⁸F-Radiolabeled Camelid Single-Domain Antibody Fragments. Journal of Nuclear Medicine, 2015, 56, 1265-1271.	2.8	139
87	Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm. Immunobiology, 2015, 220, 200-209.	0.8	27
88	Abstract 330: Ezetimibe Prevents Atherogenesis Through Increased Catabolism and Fecal Excretion of LDL-cholesterol and Reduced Atherosclerotic Plaque Inflammation in Apolipoprotein E Knock-out Mice Fed a Paigen Diet. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0
89	Nanobody-based PET/CT imaging of HER2 expression in breast carcinoma: Phase I results and potential to assess tumor heterogeneity.. Journal of Clinical Oncology, 2015, 33, e11600-e11600.	0.8	0
90	Targeted Radionuclide Therapy with A ¹⁷⁷Lu-labeled Anti-HER2 Nanobody. Theranostics, 2014, 4, 708-720.	4.6	165

#	Article	IF	Citations
91	Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia, 2014, 28, 444-447.	3.3	68
92	^{99m}Tc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice. Journal of Nuclear Medicine, 2014, 55, 1678-1684.	2.8	43
93	Specific Targeting of Atherosclerotic Plaques in ApoEâˆ'/âˆ' Mice Using a New Camelid sdAb Binding the Vulnerable Plaque Marker LOX-1. Molecular Imaging and Biology, 2014, 16, 690-698.	1.3	25
94	Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Contrast Media and Molecular Imaging, 2014, 9, 211-220.	0.4	57
95	Improved Tumor Targeting of Anti-HER2 Nanobody Through <i>N</i>-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling. Journal of Nuclear Medicine, 2014, 55, 650-656.	2.8	77
96	Camelid reporter gene imaging: a generic method for in vivo cell tracking. EJNMMI Research, 2014, 4, 32.	1.1	4
97	Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging. Bioconjugate Chemistry, 2014, 25, 979-988.	1.8	135
98	Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis. Journal of Nuclear Medicine, 2014, 55, 824-829.	2.8	47
99	Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opinion on Drug Delivery, 2014, 11, 1939-1954.	2.4	88
100	SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis. Journal of Nuclear Medicine, 2013, 54, 807-814.	2.8	80
101	Synthesis, Preclinical Validation, Dosimetry, and Toxicity of ⁶⁸Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. Journal of Nuclear Medicine, 2013, 54, 776-784.	2.8	173
102	Camelid single-domain antibody-fragment engineering for (pre)clinical<i>in vivo</i>molecular imaging applications: adjusting the bullet to its target. Expert Opinion on Biological Therapy, 2013, 13, 1149-1160.	1.4	105
103	Nanobodies and their potential applications. Nanomedicine, 2013, 8, 1013-1026.	1.7	252
104	Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nuclear Medicine and Biology, 2013, 40, 52-59.	0.3	91
105	Surface display of a single-domain antibody library on Gram-positive bacteria. Cellular and Molecular Life Sciences, 2013, 70, 1081-1093.	2.4	53
106	SAT0075â€…The use of macrophage mannose receptor-targeting nanobodies and spect imaging to study joint inflammation in mice with collagen-induced arthritis. Annals of the Rheumatic Diseases, 2013, 71, 495.2-495.	0.5	0
107	Nanobody-Based Targeting of the Macrophage Mannose Receptor for Effective <i>In Vivo</i> Imaging of Tumor-Associated Macrophages. Cancer Research, 2012, 72, 4165-4177.	0.4	263
108	Generation of Single Domain Antibody Fragments Derived from Camelids and Generation of Manifold Constructs. Methods in Molecular Biology, 2012, 907, 145-176.	0.4	124

#	Article	IF	Citations
109	Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology, 2012, 217, 1266-1272.	0.8	38
110	Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions. Circulation Research, 2012, 110, 927-937.	2.0	167
111	Molecular Imaging Using Nanobodies: A Case Study. Methods in Molecular Biology, 2012, 911, 559-567.	0.4	18
112	Site-Specific Labeling of His-Tagged Nanobodies with 99mTc: A Practical Guide. Methods in Molecular Biology, 2012, 911, 485-490.	0.4	37
113	Development of ¹⁷⁷Luâ€nanobodies for radioimmunotherapy of HER2â€positive breast cancer: evaluation of different bifunctional chelators. Contrast Media and Molecular Imaging, 2012, 7, 254-264.	0.4	70
114	Nanobody-coupled microbubbles as novel molecular tracer. Journal of Controlled Release, 2012, 158, 346-353.	4.8	78
115	Preclinical screening of antiâ€HER2 nanobodies for molecular imaging of breast cancer. FASEB Journal, 2011, 25, 2433-2446.	0.2	246
116	Specific Cell Targeting with Nanobody Conjugated Branched Gold Nanoparticles for Photothermal Therapy. ACS Nano, 2011, 5, 4319-4328.	7.3	338
117	Immuno-imaging using nanobodies. Current Opinion in Biotechnology, 2011, 22, 877-881.	3.3	109
118	Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tumor Burden: A Tool for Noninvasive Monitoring of Tumor Response to Therapy. Molecular Imaging and Biology, 2011, 13, 940-948.	1.3	51
119	Localization, mechanism and reduction of renal retention of technetiumâ€99m labeled epidermal growth factor receptorâ€specific nanobody in mice. Contrast Media and Molecular Imaging, 2011, 6, 85-92.	0.4	108
120	In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT. Journal of Nuclear Medicine, 2010, 51, 1099-1106.	2.8	106
121	Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types. Journal of Nuclear Medicine, 2010, 51, 782-789.	2.8	102
122	Overexpression of protease inhibitorâ€dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer <i>in vitro</i> and <i>in vivo</i>. Cancer Science, 2009, 100, 434-440.	1.7	35
123	Classical and alternative activation of macrophages: different pathways of macrophage-mediated tumor promotion. , 2008, , 139-156.		1
124	The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis, 2007, 29, 466-472.	1.3	39
125	The Tumor-Promoting Effect of TNF-Î± Involves the Induction of Secretory Leukocyte Protease Inhibitor. Journal of Immunology, 2006, 177, 8046-8052.	0.4	20
126	Secretory Leukocyte Protease Inhibitor in Cancer Development. Annals of the New York Academy of Sciences, 2004, 1028, 380-389.	1.8	47

#	Article	IF	Citations
127	Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5778-5782.	3.3	92
128	The regulated expression of an intrabody produces a mutant phenotype inDrosophila. FEBS Letters, 1998, 437, 81-86.	1.3	6
129	Effects of Altered Antigen Processing on H-2Dk Mediated NK Inhibition in a Murine T Lymphoma Model. Advances in Experimental Medicine and Biology, 1998, 451, 237-240.	0.8	0
130	Effects of Altered Antigen Processing on T-Cell Responses Toward Murine T-Lymphomas. Advances in Experimental Medicine and Biology, 1998, 451, 211-215.	0.8	0
131	Radiotheranostic Agents in Hematological Malignancies. Frontiers in Immunology, 0, 13, .	2.2	5